Hua Dong

1.2k total citations
28 papers, 691 citations indexed

About

Hua Dong is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Hua Dong has authored 28 papers receiving a total of 691 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Genetics. Recurrent topics in Hua Dong's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and CAR-T cell therapy research (3 papers). Hua Dong is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and CAR-T cell therapy research (3 papers). Hua Dong collaborates with scholars based in China, United States and Germany. Hua Dong's co-authors include Srđan Verstovšek, Julia D. Maltzman, Johanna C. Bendell, J. Randolph Hecht, Al B. Benson, Zev A. Wainberg, Fred J. Kudrik, Vikas Gupta, Alessandro M. Vannucchi and Uwe Platzbecker and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Hua Dong

25 papers receiving 685 citations

Peers

Countries citing papers authored by Hua Dong

Since Specialization

Citations

This map shows the geographic impact of Hua Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hua Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hua Dong more than expected).

Fields of papers citing papers by Hua Dong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hua Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hua Dong. The network helps show where Hua Dong may publish in the future.

Co-authorship network of co-authors of Hua Dong

This figure shows the co-authorship network connecting the top 25 collaborators of Hua Dong. A scholar is included among the top collaborators of Hua Dong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hua Dong. Hua Dong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Case Report: Exogenous insulin antibody syndrome complicated with chronic renal failure and long-term history of type 2 diabetes: report of two cases 2025 ·Frontiers in Endocrinology ·Zhiwei Hu, Xiaozhu Huang, Jun Pan, Hua Dong	0
2	A novel pan-epitope based nanovaccine self-assembled with CpG enhances immune responses against flavivirus 2024 ·Journal of Nanobiotechnology ·(unknown), Xiaoyan Ding, Jing Zhao, Jie Zeng, Yuxin Zhou, Wen Xiao, Hua Dong, (unknown), (unknown), Liang Yu, (unknown), Jintao Li	5
3	Enhancing Dengue Virus Production and Immunogenicity with Celcradle™ Bioreactor: A Comparative Study with Traditional Cell Culture Methods 2024 ·Vaccines ·(unknown), Xiaoyan Ding, Hua Dong, (unknown), Maocheng Yang, (unknown), Nan Ye, (unknown), (unknown), Yu Zhang, (unknown), Jintao Li	1
4	Clinicopathological characteristics and associated factors of idiopathic membranous nephropathy with hyperuricemia: a single-centered cross-sectional study 2023 ·International Urology and Nephrology ·Liang Dong, Hui Zhang, (unknown), Xiuhua Wu, (unknown), Hua Dong, Yaning Wang, Zhenmin Chen, Yunqi Liu, Xiaomin Zhang	2
5	Effective Infection with Dengue Virus in Experimental Neonate and Adult Mice through the Intranasal Route 2022 ·Viruses ·(unknown), (unknown), Junjie Zhang, Yalan Wang, (unknown), Hua Dong, Xiaoyan Ding, Xiaoyang Zhou, Jie Zeng, Huacheng Yan, Jintao Li	5
6	Benchmarking the Human Leukocyte Antigen Typing Performance of Three Assays and Seven Next-Generation Sequencing-Based Algorithms 2021 ·Frontiers in Immunology ·Ping Liu, Minya Yao, (unknown), Xue Song, (unknown), Yizhou Ye, Xiao Liu, Fugen Li, Hua Dong, Rui Meng, (unknown), (unknown)	21
7	Abstract 2044: Genomic scar score: a robust model to predict recombination repair deficient based on genomic instability 2021 ·Cancer Research ·Hao Wen, Shuang Yang, Xuejun Chen, (unknown), Changbin Zhu, Li Ruan, Hua Dong, Xiaohua Wu	1
8	Danshensu attenuates cisplatin-induced nephrotoxicity through activation of Nrf2 pathway and inhibition of NF-κB 2021 ·Biomedicine & Pharmacotherapy ·(unknown), Hua Dong, Qingchen Wang, (unknown), Yanni Li, Juanjuan Zhao, Jiazhu Li	32
9	Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction 2021 ·Blood ·Frederick L. Locke, Caron A. Jacobson, Long Ma, Hua Dong, Zhen‐Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel‐Angel Perales, Matthew A. Lunning, Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Abu‐Sayeef Mirza, Sarah Nikiforow, Hairong Xu, Marcelo C. Pasquini	11
10	Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US) 2019 ·Blood ·Marcelo C. Pasquini, Frederick L. Locke, Alex F. Herrera, Tanya Siddiqi, Armin Ghobadi, Krishna V. Komanduri, Zhen‐Huan Hu, Hua Dong, Peiman Hematti, Sarah Nikiforow, Patricia Steinert, Anna Purdum, Mary M. Horowitz, (unknown), Jun Kawashima, Caron A. Jacobson	72
11	Abstract 5137: Comprehensive analysis of POLE and POLD1 mutation in 9322 Chinese cancer patients 2019 ·Cancer Research ·Hua Dong, Yuezong Bai, Xinkai Cao, Yanyan Wang, (unknown), Fugen Li, Yizhou Ye, Shuyang Sun	2
12	Effects of recombinant human growth hormone on protein malnutrition and IGF-1 and IL-2 gene expression levels in chronic nephrotic syndrome 2018 ·Experimental and Therapeutic Medicine ·(unknown), Donghai Wang, Hua Dong	2
13	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial 2017 ·The Lancet Haematology ·Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker, Francisco Cervantes, Vikas Gupta, David Lavie, Francesco Passamonti, Elliott F. Winton, Hua Dong, Jun Kawashima, Julia D. Maltzman, Jean‐Jacques Kiladjian, Srđan Verstovšek	212
14	A phase 2 study of simtuzumab in patients with primary, post‐polycythaemia vera or post‐essential thrombocythaemia myelofibrosis 2017 ·British Journal of Haematology ·Srđan Verstovšek, Michael R. Savona, Ruben A. Mesa, Hua Dong, Julia D. Maltzman, (unknown), Jeffrey A. Silverman, Stephen T. Oh, Jason Gotlib	42
15	Association between cystatin C and the interaction of pulmonary tuberculosis with chronic diseases 2017 ·Tropical Journal of Pharmaceutical Research ·Huan Wu, (unknown), Yufeng Wen, Dan Xia, Mengxue Liu, Jun Ma, (unknown), Hua Dong	0
16	Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX). 2017 ·Journal of Clinical Oncology ·Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker, Francisco Cervantes, Vikas Gupta, David Lavie, Francesco Passamonti, Elliott F. Winton, Hua Dong, Jun Kawashima, Julia D. Maltzman, Jean‐Jacques Kiladjian, Srđan Verstovšek	14
17	Association of fibronectin Msp iv polymorphism and diabetic nephropathy susceptibility in Chinese Han population. 2015 ·PubMed ·(unknown), Xuezhong Zhang, (unknown), (unknown), Min Lv, Hua Dong, Xiaomin Zhang, Yaning Wang	1
18	A phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of simtuzumab (GS-6624) combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. 2013 ·Journal of Clinical Oncology ·Al B. Benson, (unknown), Michael Hawkins, (unknown), Hua Dong, Claudia Lee, Johanna C. Bendell	4
19	Novel Rapid Molecular Modeling Method Based on Evolutional Tree for Human Adenovirus Hexon Proteins Family 2011 ·Gaodeng xuexiao huaxue xuebao ·Xiaohui Yuan, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Hua Dong, Xiaomin Wu, Zhiwei Yang, Hong Gao	4
20	Sodium Selenite Induces Apoptosis in Acute Promyelocytic Leukemia-Derived NB4 Cells Through Mitochondria-Dependent Pathway 2009 ·Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics ·Bingshe Han, Yun Ren, (unknown), Wei Wei, Fangyuan Hua, Yang Yang, Tao Yang, (unknown), Hua Dong, (unknown), (unknown)	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact